APA (7th ed.) Citation

Gao, Z., Mao, Y., Sun, Y., Tong, L., Liu, H., Wang, T., . . . Yan, X. (2025). Three‐Year Follow‐Up of the Phase II Trial for Resectable Non‐Small‐Cell Lung Cancer Treated With Perioperative Sintilimab and Neoadjuvant Anlotinib Plus Chemotherapy: TD‐NeoFOUR Trial. Thoracic Cancer, 16(16), 1. https://doi.org/10.1111/1759-7714.70149

Chicago Style (17th ed.) Citation

Gao, Zhiyuan, Yajie Mao, Yichen Sun, Liping Tong, Honggang Liu, Tianhu Wang, Changjian Shao, Hongtao Duan, and Xiaolong Yan. "Three‐Year Follow‐Up of the Phase II Trial for Resectable Non‐Small‐Cell Lung Cancer Treated With Perioperative Sintilimab and Neoadjuvant Anlotinib Plus Chemotherapy: TD‐NeoFOUR Trial." Thoracic Cancer 16, no. 16 (2025): 1. https://doi.org/10.1111/1759-7714.70149.

MLA (9th ed.) Citation

Gao, Zhiyuan, et al. "Three‐Year Follow‐Up of the Phase II Trial for Resectable Non‐Small‐Cell Lung Cancer Treated With Perioperative Sintilimab and Neoadjuvant Anlotinib Plus Chemotherapy: TD‐NeoFOUR Trial." Thoracic Cancer, vol. 16, no. 16, 2025, p. 1, https://doi.org/10.1111/1759-7714.70149.